Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01303081 · ClinicalTrials.gov registry record · NA
Pilot Randomized Control Trial of Financial Incentives for Smoking Cessation
A NA study, sponsored by University of Pennsylvania.
- Completed
- Registry status
- NA
- Development phase
- 63
- Enrollment target
NCT01303081: Completed NA study, sponsored by University of Pennsylvania.
NCT01303081 is a NA study that has completed, run by University of Pennsylvania. The registered enrollment target is 63 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (96% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01303081, a NA study, has completed, sponsored by University of Pennsylvania.
- COMPLETED
- Registry status
- NA
- Development phase
- 63 participants
- Enrollment target
Study Summary
Financial incentives may be more effective than other approaches to smoking cessation, but research is needed to identify the optimal structures of incentives. The investigators will conduct a pilot randomized trial comparing different incentive structures for smoking cessation. Collaborating with Walgreens leadership, the investigators will enroll their employees in this RCT using the investigators new web-based research infrastructure (called the Way to Health platform, and approved as a Prime protocol by the IRB as reference # 811860). Hypothesis: providing patients with financial incentives can promote healthier behaviors (e.g.: quit smoking).
Primary Outcome
The primary measure of smoking cessation will be prolonged abstinence for 3 months, which will be measured by salivary cotinine testing or by urinary anabasine testing (for those participants using nicotine replacement therapy). Saliva samples will be analyzed using semi-quantitative immunochromatographic assay test strips at the University of Pennsylvania. Urine samples will be analyzed using gas chromatography at the Associated Regional and University Pathologists (ARUP) Lab, at the University
Interventions
- BEHAVIORAL Usual Care
- BEHAVIORAL Individual Rewards
- BEHAVIORAL Fixed Deposits
- BEHAVIORAL Competitive Deposits (Pari-Mutuel)
- BEHAVIORAL Chosen Deposits
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 63 participants |
| Start Date | 2011-06 |
| Est. Completion | 2012-06 |
| Phase | NA |
What the finished NCT01303081 record still lists
NCT01303081 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 63 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (96% lower).
The record links to 0 conditions, and to 5 interventions - of which Usual Care is the first listed.
NCT01303081 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01303081 about?
NCT01303081 is a clinical study titled "Pilot Randomized Control Trial of Financial Incentives for Smoking Cessation". Financial incentives may be more effective than other approaches to smoking cessation, but research is needed to identify the optimal structures of incentives. The investigators will conduct a pilot randomized trial comparing different incentive structures for smoking cessation. Collaborating with W...
What is the current status of trial NCT01303081?
This trial is currently completed. It is a NA study. The enrollment target is 63 participants. The study started on 2011-06. Estimated completion is 2012-06.
What interventions are being tested in trial NCT01303081?
The interventions under investigation include: Usual Care (BEHAVIORAL), Individual Rewards (BEHAVIORAL), Fixed Deposits (BEHAVIORAL), Competitive Deposits (Pari-Mutuel) (BEHAVIORAL), Chosen Deposits (BEHAVIORAL).
Who is sponsoring clinical trial NCT01303081?
This trial is sponsored by University of Pennsylvania, which has 1,423 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01303081's enrollment target sits among peer trials
63 1157th of 2000 higher than 844 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03383575 · 63 participants · Phase 2
Azacitidine and Enasidenib in Treating Patients With IDH2-Mutant Myelodysplastic Syndrome
- NCT04870944 · 63 participants · Phase 1
CBL0137 for the Treatment of Relapsed or Refractory Solid Tumors, Including CNS Tumors and Lymphoma
- NCT05031897 · 63 participants · Phase 2
Two Step Haplo With Radiation Conditioning
- NCT05312671 · 63 participants · Phase 2
Atezolizumab Plus Etoposide and Platinum in Small Cell Bladder Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia